Thras Karydis is the Co-Founder and Chief Technology Officer at DeepCure, a cutting-edge biotechnology company driving the discovery of novel small molecule therapies for inflammation and immunology indications. He developed DeepCure's groundbreaking core technology and is a thought leader and international speaker on computational tools and software for small molecule design and automated chemistry. Thras is an alumnus of Massachusetts Institute of Technology (MIT) Media Lab and MIT Center for Bits and Atoms, where his research was focused on Deep Learning for Protein Design. DeepCure has made significant strides, including their recent announcement of DC-15442--a potent, selective, oral STAT6 inhibitor--as their second development candidate.